Key Features
Enhance your research with our curated data sets and powerful platform features. Pluto Bio makes it simple to find and use the data you need.
Learn MoreLocal administration of IFN--producing proliferating myeloid cells (IFN--iPSC-pMCs) inhibited the tumor growth not only at the treatment site (right) but also at the distant site (left). We identified genes with log fold expression change 1 or 1 in untreated versus IFN--iPSC-pMC-treated tumors and iPSC-pMC-treated versus IFN--iPSC-pMC-treated tumors for treatment or distant site, respectively. Of the overlapping genes differentially expressed in IFN--iPSC-pMC-treated mice, 301/671 distant site and 460/928 treated site genes were ISGs, of which 95.3% and 94.7%, respectively, were type I IFN-related. By gene ontology, the up-regulated ISG signatures were enriched for T cell-mediated immune responses, cytolysis, and migration of immune cells associated genes. Collectively, Local administration of IFN--iPSC-pMCs alters the tumor microenvironment and propagates molecular signature associated with type I IFN. SOURCE: Ranmaru Shimoda (shimoda@rhelixa.com) - Rhelixa, Inc.
View on GEOView in PlutoEnhance your research with our curated data sets and powerful platform features. Pluto Bio makes it simple to find and use the data you need.
Learn MoreUse Pluto's intuitive interface to analyze and visualize data for this experiment. Pluto's platform is equipped with an API & SDKs, making it easy to integrate into your internal bioinformatics processes.
Read about post-pipeline analysisView quality control data and experiment metadata for this experiment.
Request imports from GEO or TCGA directly within Pluto Bio.
Chat with our Scientific Insights team